To extract the evidenced benefits attained from the simultaneousinhibition of multiple targets in cancer, Merlino et al. in 2018 reporteda series of RGD integrins and dual MDM protein inhibitors to treatGBM.89 The group considered the chemicalarchitecture of previously reported compounds 134 and 135 as a lead compound for the structural optimization program.Thus, 135 showed good integrin inhibitory potential coupledwith a magnificent activity profile toward MDM2 and MDM4 (IC50 = 437 and 219 nM, respectively). This evidence concerns the gene MDM2 and cancer.